Sentence: Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['tremelimumab', 'sunitinib'], 'is_context_needed': True}]